Calcitonin Salmon

Treats symptomatic Paget’s disease of bone. Sold as Calcimar, Miacalcin. Every FDA application for this active ingredient: 4 branded and 12 generic.

As of Nov 15, 2026, FDA lists 16 applications for Calcitonin Salmon (sold as Calcimar, Miacalcin), first approved Apr 17, 1978, with 0 new uses approved and 0 published complete response letters.

First approved: Apr 17, 1978
Applications: 16
New uses approved: 0
Complete response letters: 0

What Pharmacies Pay

Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change

CALCITONIN-SALMON 200 UNIT SPR: $13.51 per MLGeneric · +4% in a year

Clinical Trials

26 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all


Effects of a Preoperative Capsaicin-Containing Diet on Postoperative Liver Injury RepairPostoperative Liver Injury · Tongji Hospital	Not applicable	Not yet recruiting	Nov 9, 2026
Psychological Support for Chronic Migraine Patients Treated With Anti-CGRP (Anti-Calcitonin Gene-Related Peptide ) Monoclonal AntibodiesChronic Migraine Headache, Psychologic Adaptation · Central Hospital, Nancy, France	—	Not yet recruiting	Oct 16, 2026
A Phase 1 Study of VK3019 in Overweight and Obese Adults Without ComorbiditiesObese Adults · Viking Therapeutics, Inc.	Phase 1	Recruiting	Sep 29, 2026
Effect of Atogepant on the Vestibulo-Ocular Reflex in Healthy Adults and Adults With MigraineMigraine Disorders, Brain, Healthy Adult Participants · Konrad Peter Weber	Phase 4	Not yet recruiting	Sep 17, 2026
Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell CarcinomaOral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (OPSCC) · Shanghai Zhongshan Hospital	Phase 2	Not yet recruiting	Sep 10, 2026
Effect of Nebulized Dexmedetomidine on Central Sensitization and Chronification in MigraineChronic Migraine · Beni-Suef University	Not applicable	Recruiting	Aug 17, 2026
Different Kinematics Within a Single-File System and Postoperative PainRoot Canal Treatment, Postoperative Pain · Jordan University of Science and Technology	Not applicable	Active, not recruiting	Jul 13, 2026
Subcutaneous Calcitonin in Acute Herpes ZosterCalcitonin, Subcutaneous · Tanta University	Phase 3	Recruiting	Jun 18, 2026

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history


Apr 17, 1978	CalcimarNDA 17769 · New dosage form	Sanofi Aventis US	21	Discontinued
Jul 3, 1986	MiacalcinNDA 17808 · New formulation or manufacturer	Mylan Ireland Ltd	27	Marketed
Aug 17, 1995	MiacalcinNDA 20313 · New dosage form	Saptalis Pharms	22	Discontinued
Nov 17, 2008	Calcitonin-SalmonANDA 76396	Apotex Inc	3	Marketed
Jun 8, 2009	Calcitonin-SalmonANDA 76979	Ph Health	4	Marketed
May 14, 2021	Calcitonin-SalmonANDA 212416	Custopharm Inc	0	Marketed
Nov 10, 2021	Calcitonin-SalmonANDA 209358	Ph Health	0	Marketed
Apr 11, 2024	Calcitonin-SalmonANDA 215715	Dr Reddys	0	Marketed
Sep 20, 2024	Calcitonin-SalmonANDA 213766	Cipla	0	Marketed
Dec 5, 2024	Calcitonin-SalmonANDA 212675	Fresenius Kabi USA	0	Marketed
Jul 9, 2025	Calcitonin-SalmonANDA 219196	Sagent	0	Marketed
Sep 26, 2025	Calcitonin-SalmonANDA 216294	Amneal	0	Marketed
Mar 4, 2026	Calcitonin-SalmonANDA 215864	Zydus Pharms	0	Marketed
Oct 29, 2026	Calcitonin-SalmonANDA 216996	Nanjing King Friend	0	Marketed
—	Calcitonin-SalmonANDA 73690	Igi Labs Inc	0	Discontinued
—	CalcimarNDA 17497	Sanofi Aventis US	0	Discontinued

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA